Study of CS-7017 in Colorectal Cancer Patients Who Have Achieved Disease Control Following First-Line Chemotherapy
Stopped Due to changes to the standard of care within the proposed market for CS-7017.
Conditions
Interventions
- DRUG: CS-7017
- DRUG: Placebo
Sponsor
Daiichi Sankyo